Lodoxamide in vernal keratoconjunctivitis

Abstract

Lodoxamide may be superior compared with cromolyn sodium for treatment of VKC. It is difficult, however, to conclusively determine the superiority of lodoxamide compared with cromolyn from the three studies reviewed in this article. Optimally, a triple-blind, randomized, placebo-controlled, multicenter trial involving the ophthalmic products cromolyn sodium 4%, lodoxamide 0.1%, and placebo (preferably NaCl 0.9%) with a treatment duration of at least 90 days and a similar sample size for each study group would lend the most credence to the determination of superiority of lodoxamide compared with cromolyn sodium for the treatment of VKC.